4N7G

Crystal structure of 14-3-3zeta in complex with a peptide derived from ExoS

Summary for 4N7G

• Entry DOI: 10.2210/pdb4n7g/pdb
• Related: 3CH8 3NKX 4IEA 4IHL 4N7Y 4N84
• Descriptor: 14-3-3 protein zeta/delta, Exoenzyme S, HEXAETHYLENE GLYCOL, ... (4 entities in total)
• Functional Keywords: 14-3-3, adaptor protein, protein-protein interaction, cross-link, signaling protein
• Biological source: Homo sapiens (human); More
• Cellular location: Cytoplasm: P63104
• Total number of polymer chains: 2
• Total formula weight: 29247.11

Authors

Bier, D.,Glas, A.,Hahne, G.,Grossmann, T.,Ottmann, C. (deposition date: 2013-10-15, release date: 2014-02-19, Last modification date: 2024-02-28)

Primary citation

Glas, A.,Bier, D.,Hahne, G.,Rademacher, C.,Ottmann, C.,Grossmann, T.N.
Constrained peptides with target-adapted cross-links as inhibitors of a pathogenic protein-protein interaction.
Angew.Chem.Int.Ed.Engl., 53:2489-2493, 2014

PubMed Abstract: Bioactive conformations of peptides can be stabilized by macrocyclization, resulting in increased target affinity and activity. Such macrocyclic peptides proved useful as modulators of biological functions, in particular as inhibitors of protein-protein interactions (PPI). However, most peptide-derived PPI inhibitors involve stabilized α-helices, leaving a large number of secondary structures unaddressed. Herein, we present a rational approach towards stabilization of an irregular peptide structure, using hydrophobic cross-links that replace residues crucially involved in target binding. The molecular basis of this interaction was elucidated by X-ray crystallography and isothermal titration calorimetry. The resulting cross-linked peptides inhibit the interaction between human adaptor protein 14-3-3 and virulence factor exoenzyme S. Taking into consideration that irregular peptide structures participate widely in PPIs, this approach provides access to novel peptide-derived inhibitors.

PubMed: 24504455
DOI: 10.1002/anie.201310082

Experimental method

X-RAY DIFFRACTION (2.25 Å)